AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 39707209
Drug: Conservative oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative oxygen therapy (target SpO2 of 88-92%)
Trial: 39707239
Drug: Drug tapering
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug tapering and treatment for underlying psychiatric disorders
Trial: 39707287
Drug: Self-administered care
RxNorm normalized name: Lactomedi Self-care Trial Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered care recommendations (C-group)
Trial: 39707407
Drug: Perioperative methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative methadone (0.10 mg/kg, administered intravenously at anesthesia induction)
Trial: 39708086
Drug: 2G oral
RxNorm normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2G oral semaglutide (9 mg)
Trial: 39708086
Drug: 2G oral
RxNorm normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2G oral semaglutide (4 mg)
Trial: 39708086
Drug: 2G oral
RxNorm normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2G oral semaglutide (1.5 mg)
Trial: 39708086
Drug: 2G oral
RxNorm normalized name: Mesalamine 1.2g Oral tablet, gastro-resistant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2G oral semaglutide
Trial: 39708224
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing from a Registered Dietitian (RDMI) during a 6-month intensive Food is Medicine (FIM) intervention
Trial: 39708245
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (25-40 W applications, unlimited duration)
Trial: 39708369
Drug: Topical ruxolitinib
RxNorm normalized name: ruxolitinib Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ruxolitinib 1.5% cream applied twice daily for 16 weeks
Trial: 39708369
Drug: Topical ruxolitinib
RxNorm normalized name: ruxolitinib Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ruxolitinib treatment
Trial: 39708537
Drug: Pressurized IntraThoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin (PITHAC) with doses of 7.5-12.5-35-70 mg/m2 heated at 39±1 °C
Trial: 39708826
Drug: LVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVA therapy (2 g amoxicillin: 1 g twice a day)
Trial: 39708826
Drug: HVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVA therapy (3 g amoxicillin: 1 g three times a day)
Trial: 39708826
Drug: LVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LVA therapy
Trial: 39708826
Drug: HVA therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVA therapy
Trial: 39709140
Drug: HEC88473 (30.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC88473 (30.6 mg)
Trial: 39709140
Drug: HEC88473 (68.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC88473 (68.0 mg)
Trial: 39709368
Drug: Multidisciplinary team
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidisciplinary team assessment and individualized treatment (MDT)
Trial: 39709372
Drug: PULSAR with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PULSAR with HyperArc© software, 11 Gray fraction of radiation every two weeks for a total of five fractions (total dose of 55 Gy)
Trial: 39709402
Drug: L-PRF loaded
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF loaded with Metronidazole
Trial: 39710508
Drug: Dostarlimab monotherapy
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab monotherapy (Arm A)
Trial: 39710508
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of chemotherapy (Arm C)
Trial: 39710693
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone (20 mg/day on days 1-5, 10 mg/day on days 6-10)
Trial: 39710693
Drug: Standard-dose dexamethasone
RxNorm normalized name: dexamethasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose dexamethasone (6 mg/day, days 1-10)
Trial: 39710693
Drug: Standard-dose dexamethasone
RxNorm normalized name: dexamethasone Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose dexamethasone
Trial: 39710697
Drug: Guideline-recommended ICG
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guideline-recommended ICG administration scheme
Trial: 39711194
Drug: Propolis-based protocol
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis-based protocol for oral health in palliative care
Trial: 39711425
Drug: Vancomycin administration
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin administration with negative pressure wound therapy (NPWT)
Trial: 39711557
Drug: Medications for
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications for opioid use disorder (MOUD)
Trial: 39711557
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to treatment initiation and retention
Trial: 39711560
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention for acute myocardial infarction diagnosis and treatment
Trial: 39711702
Drug: Citalopram with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram with prolonged grief disorder therapy (PGDT)
Trial: 39711702
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo with PGDT
Trial: 39711702
Drug: Pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pill placebo with clinical management
Trial: 39711792
Drug: Intra-arterial cocktail
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial cocktail therapy with argatroban, dexamethasone, and edaravone administered for 30 minutes into the culprit artery after sufficient recanalization.
Trial: 39712511
Drug: Dyadic Mindfulness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dyadic Mindfulness Self-Compassion intervention (six weekly sessions)
Trial: 39713041
Drug: ANG1005 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANG1005 (600 mg/m2)
Trial: 39713795
Drug: Pharmaceutical intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical intervention to improve adherence to PPI; 122 out of 178 non-adherent patients received the intervention.
Trial: 39713935
Drug: Domagrozumab (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domagrozumab (an antibody-targeting myostatin)
Trial: 39714546
Drug: Nintedanib 150
RxNorm normalized name: nintedanib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib 150 mg capsules twice daily
Trial: 39714936
Drug: Predictive low-glucose
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive low-glucose suspend insulin delivery
Trial: 39714936
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump insulin delivery
Trial: 39715568
Drug: Probiotic drink
RxNorm normalized name: CVS Probiotic Drink Mix 10 Billion CFU Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic drink containing Bifidus ActiRegularis (5x10^8) strain, administered once a day for 15 consecutive days.
Trial: 39715568
Drug: Non-pharmaceutical standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmaceutical standard care treatment (Control).
Trial: 39715573
Drug: VDOT (Video
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDOT (Video Directly Observed Therapy)
Trial: 39715573
Drug: UCDOT (Usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCDOT (Usual Care Directly Observed Therapy)
Trial: 39715755
Drug: Toripalimab plus
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab plus chemotherapy
Trial: 39716442
Drug: Acalabrutinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib treatment (n=23, NP group)
Trial: 39716442
Drug: Acalabrutinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib treatment (n=18, PD group)
Trial: 39716442
Drug: High surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High surface expression of CD49d and CD79b prior to acalabrutinib therapy
Trial: 39716875
Drug: TAK-754 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAK-754 gene therapy
Trial: 39717281
Drug: Derived DVT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derived DVT score with D-dimer cutoff of <0.5 µg/mL
Trial: 39717517
Drug: Hydroxyurea therapy
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea therapy (daily administration, escalated to maximum tolerated dose over 36 months)
Trial: 39717667
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa with chemotherapy (first-line treatment in cohorts A, B, C)
Trial: 39717667
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa with chemotherapy (second-line treatment in cohort D)
Trial: 39717777
Drug: SM17 (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM17 (2, 20, 70, 200, 400, 600, 1200 mg)
Trial: 39717777
Drug: SM17 (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM17 (200, 400, 600 mg) every two weeks (Q2W) for a total of 3 doses
Trial: 39717777
Drug: SM17 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM17 (up to 1200 mg)
Trial: 39718172
Drug: Weekly dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly dihydroartemisinin-piperaquine (approximately 2.5 mg per kg bodyweight dihydroartemisinin and 20 mg per kg bodyweight per day piperaquine)
Trial: 39718172
Drug: Monthly sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly sulfadoxine-pyrimethamine (approximately 25 mg per kg bodyweight sulfadoxine and 1.25 mg per kg bodyweight)
Trial: 39718172
Drug: Weekly dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly dihydroartemisinin-piperaquine
Trial: 39718599
Drug: Egg-protein hydrolysate
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg-protein hydrolysate (NWT-03) 5.7 g
Trial: 39718747
Drug: belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: belantamab mafodotin (2.5 mg/kg on Day 1 of each 21-day cycle) plus bortezomib and dexamethasone (Arm A)
Trial: 39718747
Drug: belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: belantamab mafodotin (2.5 mg/kg on Day 1 of the first 28-day cycle; 1.9 mg/kg on Day 1 of subsequent cycles) plus pomalidomide and dexamethasone (Arm B)
Trial: 39718991
Drug: rVSV-ZEBOV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rVSV-ZEBOV vaccine
Trial: 39719248
Drug: Empowerment intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empowerment intervention (phone-based, 3 weekly sessions)
Trial: 39719248
Drug: Education intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Education intervention (phone-based, 3 weekly sessions)
Trial: 39719276
Drug: Questionnaire addressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Questionnaire addressing general health, sleep quality, dietary habits, oral hygiene habits, and parafunctional habits
Trial: 39719429
Drug: (R)-1,3-butanediol (BD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (R)-1,3-butanediol (BD) 0.5 g/kg
Trial: 39719488
Drug: Elinzanetant 120
RxNorm normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elinzanetant 120 mg single dose
Trial: 39719545
Drug: RENEW intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RENEW intervention using the digital gamification platform Kahoot! administered across eight weekly sessions
Trial: 39719625
Drug: LHS intervention
RxNorm normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHS intervention during treatment phase
Trial: 39721062
Drug: Glittre activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glittre activities of daily living (ADL) test
Trial: 39721764
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg intravenously administered at 1-hour preblock
Trial: 39721764
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg intravenously administered at the time of the block
Trial: 39721764
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg intravenously administered at 1 hour postblock
Trial: 39721764
Drug: Dexamethasone 8
RxNorm normalized name: dexamethasone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 8 mg intravenously administered at 2 hours postblock
Trial: 39721764
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusions (placebo)
Trial: 39721851
Drug: Ipatasertib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib (400 mg as a single agent, starting with a single dose for 7 days and continuous daily dosing for 21 days, followed by 7 days off schedule)
Trial: 39721851
Drug: Ipatasertib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib (400 mg)
Trial: 39722048
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection with electroporation
Trial: 39722048
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection alone
Trial: 39722048
Drug: Needle-free injection
RxNorm normalized name: Stratis Needle-Free Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-free injection system (NFIS)
Trial: 39722400
Drug: Tildrakizumab 100
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tildrakizumab 100 mg every 12 weeks
Trial: 39722400
Drug: Placebo (switched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (switched to tildrakizumab 100 mg at W16)
Trial: 39722558
Drug: TK-OS ML
RxNorm normalized name: TK-112690
DrugBank: TK-112690 (DB18822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TK-OS ML models
Trial: 39722560
Drug: MenABCWY vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenABCWY vaccine (two doses six months apart)
Trial: 39722560
Drug: MenACWY-CRM vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-CRM vaccine (one dose)
Trial: 39722695
Drug: High-dose testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose testosterone replacement therapy (TRT) with finasteride
Trial: 39723536
Drug: Compound 21
RxNorm normalized name: COMPOUND 21
DrugBank: Buloxibutid (DB18038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound 21 infusion
Trial: 39723608
Drug: Self-administered intravaginal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intravaginal 5% fluorouracil (5FU) cream, 2 g every other week for eight applications.
Trial: 39723627
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (chemotherapy combination)
Trial: 39724020
Drug: Active PBMT
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PBMT (LED therapy: DUO 240 [red at 660nm and near-infrared at 840nm] and BIOFLEX LDR-100 laser probe (660nm red light) and LD1-200 laser probe (825nm near-infrared light))
Trial: 39724020
Drug: Placebo (non-effective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (non-effective doses of LED array and laser therapy)
Trial: 39725004
Drug: Post-treatment assessments
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment assessments
Trial: 39725051
Drug: Placebo response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo response induced through saline injection plus verbal suggestion
Trial: 39725450
Drug: Enhanced nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced nutrition package (iron and folic acid, monthly household supply of iodised salt, and micronutrient-fortified balanced energy protein supplement for undernourished women)
Trial: 39725450
Drug: Enhanced infection
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced infection management package (genitourinary tract infection screening and treatment, and enhanced deworming)
Trial: 39725795
Drug: Digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 mg daily
Trial: 39725795
Drug: Bisoprolol 5-10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5-10 mg daily
Trial: 39725982
Drug: SB-VF plus
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB-VF plus treatment as usual (TAU) (n = 41)
Trial: 39725982
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) (n = 38)
Trial: 39725982
Drug: SB-VF plus
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB-VF plus treatment as usual (TAU)
Trial: 39727027
Drug: EC-IC bypass
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC-IC bypass surgery with medical therapy
Trial: 39727027
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy (antiplatelet therapy and stroke risk factor control)
Trial: 39727053
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg single dose)
Trial: 39727283
Drug: Oxylanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxylanthanum carbonate 500 mg TID
Trial: 39727283
Drug: Oxylanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxylanthanum carbonate 1000 mg TID
Trial: 39727283
Drug: Oxylanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxylanthanum carbonate 1500 mg TID
Trial: 39727283
Drug: Oxylanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxylanthanum carbonate 2000 mg TID
Trial: 39727476
Drug: Silver Diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver Diamine Fluoride Gel
Trial: 39729067
Drug: Short-term menopausal
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term menopausal hormone therapy (mHT)
Trial: 39729347
Drug: Glucagon-Like Peptide-1
RxNorm normalized name: Glucagon-like peptide-1 (GLP-1) analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon-Like Peptide-1 Receptor Agonists
Trial: 39729347
Drug: Sodium-Glucose Cotransporter
RxNorm normalized name: glucose / sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-Glucose Cotransporter 2 Inhibitors